Continuous vs. Fixed, 3 vs 2, PFS is the primary endpoint No OS Bad crossover Lots to discuss here I will be covering all the major ASCO papers on @PlenarySession Subscribe to my substack https://vinayprasadmdmph.substack.com/
Plenary Session
4.62 - SHINE - Ibrutinib BR vs BR; Limitations to the trial
4.62 - SHINE - Ibrutinib BR vs BR; Limitations to the trial
Continuous vs. Fixed, 3 vs 2, PFS is the primary …
Plenary Session
Dr Prasad on medicine, oncology, & health policy. Host: Vinay Prasad, MD MPH from University of California San Francisco. Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com
Dr Prasad on medicine, oncology, & health policy. Host: Vinay Prasad, MD MPH from University of California San Francisco. Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.comListen on
Appears in episode
Recent Episodes
